Phase Ib Study of SC Milatuzumab in SLE

Status Completed

Clinical Trial Summary

Milatuzumab will be given subcutaneously at different dose levels once (depending on the dose level) for 4 weeks to determine if milatuzumab helps to control lupus (SLE).

Clinical Trial Description

Milatuzumab or placebo will be given subcutaneously once weekly for 4 weeks to determine if milatuzumab helps to control lupus (SLE). The treatment portion of the study lasts 4 weeks. Then patients are followed for disease activity for at least 12 weeks. If patients respond to the study drug, they may be eligible for one course of retreatment, again followed by 12 weeks of follow-up. Patients who showed a response will continue to be followed at timepoints up to one year after treatment to assess how long the response lasts. ;

Study Design

Related Conditions & MeSH terms

Lupus Erythematosus, Cutaneous
Lupus Erythematosus, Discoid
Lupus Erythematosus, Systemic
Lupus Nephritis
Lupus Vasculitis, Central Nervous System
Nephritis
Vasculitis
Vasculitis, Central Nervous System

Clinical Trial Details

NCT number	NCT01845740
Study type	Interventional
Source	Gilead Sciences
Contact
Status	Completed
Phase	Phase 1
Start date	January 2007
Completion date	June 2009

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT02936375` - The Iguratimod Effect on Lupus Nephritis (IGeLU)	Phase 2
Completed	`NCT03597464` - Aurinia Renal Assessments 2: Aurinia Renal Response in Lupus With Voclosporin	Phase 3
Recruiting	`NCT01226147` - Efficacy and Safety of Tamibarotene(AM80) for Lupus Nephritis	Phase 2
Completed	`NCT01206569` - Long-Acting Tacrolimus for the Treatment of Resistant Lupus Nephritis	Phase 4
Active, not recruiting	`NCT00569101` - A Pilot Study for the Efficacy and Safety of Tacrolimus in the Treatment of Refractory Lupus Nephritis	Phase 2
Terminated	`NCT00368264` - TNF Blockade With Remicade in Active Lupus Nephritis WHO Class V (TRIAL )	Phase 2/Phase 3
Completed	`NCT00371319` - Comparing the Efficacy of Tacrolimus and Mycophenolate Mofetil for the Initial Therapy of Active Lupus Nephritis	Phase 4
Completed	`NCT00298506` - Study to Assess the Efficacy and Safety of FK506 Combined With Mycophenolate Mofetil (MMF) in Lupus Nephritis (III/IV/V)	N/A
Completed	`NCT00094380` - Treating Systemic Lupus Erythematosus (SLE) Patients With CTLA4-IgG4m (RG2077)	Phase 1/Phase 2
Terminated	`NCT04376827` - A Study of Guselkumab in Participants With Active Lupus Nephritis	Phase 2
Completed	`NCT03610516` - Safety, Pharmacokinetics and Preliminary Efficacy Study of CFZ533 in Patients With Lupus Nephritis.	Phase 2
Recruiting	`NCT03526042` - Angiotensin-II Receptor Antibodies Blockade With Losartan in Patients With Lupus Nephritis	N/A
Withdrawn	`NCT03859570` - Pentoxifylline in Lupus Nephritis	Phase 4
Completed	`NCT03664908` - Detection of Anti-glomerular Basement Membrane Antibodies (Anti-GBM): a Promising Biomarker for Lupus Nephritis (LN)?	N/A
Completed	`NCT01085097` - A Study of Laquinimod in Participants With Systemic Lupus Erythematosus (SLE) Active Lupus Nephritis	Phase 2
Active, not recruiting	`NCT05704088` - SGLT2 Inhibitors Between Reno Protective Effects and Impact on Bone and Mineral Disease Among Lupus Nephritis Patients	Phase 4
Recruiting	`NCT02226341` - ACTHar in the Treatment of Lupus Nephritis	Phase 4
Recruiting	`NCT02453997` - Mycophenolic Acid Pharmacokinetics and Pharmacogenomics in Lupus Nephritis	N/A
Completed	`NCT01470183` - Lupus Nephritis Biomarker Study: Baseline Characteristics of Patients	N/A
Terminated	`NCT00089804` - Study of LJP 394 in Lupus Patients With History of Renal Disease	Phase 3